These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 18762932)

  • 1. No clinically relevant CYP3A induction after St. John's wort with low hyperforin content in healthy volunteers.
    Mueller SC; Majcher-Peszynska J; Mundkowski RG; Uehleke B; Klammt S; Sievers H; Lehnfeld R; Frank B; Thurow K; Kundt G; Drewelow B
    Eur J Clin Pharmacol; 2009 Jan; 65(1):81-7. PubMed ID: 18762932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose.
    Mueller SC; Majcher-Peszynska J; Uehleke B; Klammt S; Mundkowski RG; Miekisch W; Sievers H; Bauer S; Frank B; Kundt G; Drewelow B
    Eur J Clin Pharmacol; 2006 Jan; 62(1):29-36. PubMed ID: 16341856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperforin in St. John's wort drug interactions.
    Madabushi R; Frank B; Drewelow B; Derendorf H; Butterweck V
    Eur J Clin Pharmacol; 2006 Mar; 62(3):225-33. PubMed ID: 16477470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiologically Based Pharmacokinetic Modelling of Hyperforin to Predict Drug Interactions with St John's Wort.
    Adiwidjaja J; Boddy AV; McLachlan AJ
    Clin Pharmacokinet; 2019 Jul; 58(7):911-926. PubMed ID: 30675694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variability in PXR-mediated induction of CYP3A4 by commercial preparations and dry extracts of St. John's wort.
    Gödtel-Armbrust U; Metzger A; Kroll U; Kelber O; Wojnowski L
    Naunyn Schmiedebergs Arch Pharmacol; 2007 Aug; 375(6):377-82. PubMed ID: 17593354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. St. John's wort extract with a high hyperforin content does not induce P-glycoprotein activity at the human blood-brain barrier.
    El Biali M; Wölfl-Duchek M; Jackwerth M; Mairinger S; Weber M; Bamminger K; Poschner S; Rausch I; Schindler N; Lozano IH; Jäger W; Nics L; Tournier N; Hacker M; Zeitlinger M; Bauer M; Langer O
    Clin Transl Sci; 2024 May; 17(5):e13804. PubMed ID: 38700454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction and inhibition of cytochromes P450 by the St. John's wort constituent hyperforin in human hepatocyte cultures.
    Komoroski BJ; Zhang S; Cai H; Hutzler JM; Frye R; Tracy TS; Strom SC; Lehmann T; Ang CY; Cui YY; Venkataramanan R
    Drug Metab Dispos; 2004 May; 32(5):512-8. PubMed ID: 15100173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperforin contributes to the hepatic CYP3A-inducing effect of Hypericum perforatum extract in the mouse.
    Cantoni L; Rozio M; Mangolini A; Hauri L; Caccia S
    Toxicol Sci; 2003 Sep; 75(1):25-30. PubMed ID: 12857935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding drug interactions with St John's wort (Hypericum perforatum L.): impact of hyperforin content.
    Chrubasik-Hausmann S; Vlachojannis J; McLachlan AJ
    J Pharm Pharmacol; 2019 Jan; 71(1):129-138. PubMed ID: 29411879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical risks of St John's Wort (Hypericum perforatum) co-administration.
    Soleymani S; Bahramsoltani R; Rahimi R; Abdollahi M
    Expert Opin Drug Metab Toxicol; 2017 Oct; 13(10):1047-1062. PubMed ID: 28885074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the St. John's wort constituent hyperforin on docetaxel metabolism by human hepatocyte cultures.
    Komoroski BJ; Parise RA; Egorin MJ; Strom SC; Venkataramanan R
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6972-9. PubMed ID: 16203790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional induction and de-induction of P-glycoprotein by St. John's wort and its ingredients in a human colon adenocarcinoma cell line.
    Tian R; Koyabu N; Morimoto S; Shoyama Y; Ohtani H; Sawada Y
    Drug Metab Dispos; 2005 Apr; 33(4):547-54. PubMed ID: 15640377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction.
    Mai I; Bauer S; Perloff ES; Johne A; Uehleke B; Frank B; Budde K; Roots I
    Clin Pharmacol Ther; 2004 Oct; 76(4):330-40. PubMed ID: 15470332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-dependent induction of CYP3A activity by St. John's wort alone and in combination with rifampin.
    Hohmann N; Friedrichs AS; Burhenne J; Blank A; Mikus G; Haefeli WE
    Clin Transl Sci; 2024 Aug; 17(8):e70007. PubMed ID: 39152679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of pharmacokinetic data of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin revealed from single and multiple oral dose studies with a hypericum extract containing tablet in healthy male volunteers.
    Schulz HU; Schürer M; Bässler D; Weiser D
    Arzneimittelforschung; 2005; 55(10):561-8. PubMed ID: 16294501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity.
    Fuchs I; Hafner-Blumenstiel V; Markert C; Burhenne J; Weiss J; Haefeli WE; Mikus G
    Eur J Clin Pharmacol; 2013 Mar; 69(3):507-13. PubMed ID: 22968811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity.
    Wang Z; Gorski JC; Hamman MA; Huang SM; Lesko LJ; Hall SD
    Clin Pharmacol Ther; 2001 Oct; 70(4):317-26. PubMed ID: 11673747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short term treatment with St. John's wort, hypericin or hyperforin fails to induce CYP450 isoforms in the Swiss Webster mouse.
    Bray BJ; Brennan NJ; Perry NB; Menkes DB; Rosengren RJ
    Life Sci; 2002 Feb; 70(11):1325-35. PubMed ID: 11883710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of simultaneous induction and inhibition of CYP3A by St John's Wort and ritonavir on CYP3A activity.
    Hafner V; Jäger M; Matthée AK; Ding R; Burhenne J; Haefeli WE; Mikus G
    Clin Pharmacol Ther; 2010 Feb; 87(2):191-6. PubMed ID: 19924124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The recovery time-course of CYP3A after induction by St John's wort administration.
    Imai H; Kotegawa T; Tsutsumi K; Morimoto T; Eshima N; Nakano S; Ohashi K
    Br J Clin Pharmacol; 2008 May; 65(5):701-7. PubMed ID: 18294328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.